Emergence of amantadine-resistant influenza A viruses: Epidemiological study

Journal of Infection and Chemotherapy

Volumn 9, Issue 3, 2003, Pages 195-200

  Suzuki, Hiroshi ^a   Saito, Reiko ^a   Masuda, Hiroki ^a   Oshitani, Hitoshi ^a   Sato, Mizuho ^a   Sato, Isamu ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Yoiko Pediatric Clinic   (Japan)

Author keywords

Amantadine; Influenza virus; Resistant virus

Indexed keywords

AMANTADINE; AMINO ACID; ANTIVIRUS AGENT; MEMBRANE PROTEIN; OSELTAMIVIR; PROTEIN M2; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CHEMOPROPHYLAXIS; CONTACT SENSITIVITY; DISEASE COURSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HUMAN; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A; JAPAN; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; NONHUMAN; NURSING HOME; PARKINSON DISEASE; PLAQUE REDUCTION ASSAY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TITRIMETRY; VIRUS CULTURE; VIRUS PLAQUE; VIRUS RESISTANCE; VIRUS SHEDDING;

EID: 0142058503     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-003-0262-6     Document Type: Review

References (33)

1. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 1992;15:362-7.
2. Centers for Disease Control and Prevention. Prevention and control of influenza; recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC. Prevention and control of influenza: recommendations of the Advisory 2003;52(No. RR8):16-24.
3. Oxford JS, Blasingam BS, Mann A, Novelli P, Lambkin R. Treatment of epidemic and pandemic influenza with neuraminidase and M2 protein channel inhibitors. Clin Microbiol Infect 2003;9:1-14.
4. Masuda H, Suzuki H, Oshitani H, Saito R, Kawasaki S, Nishikawa M, et al. Incidence of amantadine resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan. Microbiol Immunol 2000;44:833-9.
5. Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol 2002;40:84-8.
6. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992;69:517-28.
7. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992;3:21-30.
8. Wang C, Takeuchi K, Pinto L, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993;67:5585-94.
9. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1998;62:1508-12.
10. Black RA, Rota PA, Gorodkova N, Cramer A, Klenk HD, Kendal AP. Production of the M2 protein of influenza A virus in insect cells is enhanced in the presence of amantadine. J Gen Virol 1993;74:1673-7.
11. Hayden FG, Belsche RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
12. Hayden FG, Sperber SJ, Belsche RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991;35:1741-7.
13. Hayden FG. Antiviral for pandemic influenza. J Infect Dis 1997;176(Suppl 1):S56-61.
14. Monto A. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997;176(Suppl 1):S32-7.
15. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991;180:617-24.
16. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994;68:1551-63.
17. Klimov AI, Rocha E, Hayden FG, Shult PS, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172:1352-5.
18. Saito R, Sakai T, Sato I, Sano Y, Oshitani H, Sato M, et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1, H3N2. J Clin Microbiol 2003;41:2145-6.
19. Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989;159:430-5.
20. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Arch Intern Med 1995;155:533-7.
21. Prud'homme IT, Zoueva O, Weber JM. Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample, 1991-94. Clin Diagn Virol 1997;8:41-51.
22. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998;26:1418-24.
23. Ziegler T, Hemphill ML, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999;180:935-9.
24. Dawson J. Neuraminidase inhibitor and amantadine. Lancet 2000;355:2254.
25. Suzuki H, Saito R, Oshitani H. Excess amantadine use and resistant viruses. Lancet 2001;358:1910.
26. Patriarca PA, Arden NH, Koplan JP, Goodman RA. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987;107:732-40.
27. Mast EE, Harmon MW, Gravenstein S, Wu SP, Arden NH, Circo R, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991;134:988-97.
28. Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992;152:390-2.
29. Scholtissek C, Quack G, Klenk HD, Webster RG. How to overcome resistance of influenza A viruses against amantadine derivatives. Antiviral Res 1998;37:83-95.
30. Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH, et al. Children with influenza A infection; treatment with rimantadine. Pediatrics 1987;80:275-82.
31. Sato I, Saito R, Sano Y, Sasazaki Y, Sato M, Shoji Y, et al. Treatment of influenza A infection in children with amantadine: an observation of adverse effects and resistant viruses (in Japanese). Gairaishonika 2000;3:255-9.
32. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998;177:863-73.
33. Tooley P. Unprepared for an influenza pandemic. Lancet 2001;358:670-1.